Author:
Piso Pompiliu,Aselmann H.,Dahlke M. H.,Klempnauer J.,Schlitt H. J.
Publisher
Springer Berlin Heidelberg
Reference4 articles.
1. Eggermont AMM, Steller EP, Ottow RT, Matthews W, Sugarbaker PH (1987) Augmentation of interleukin-2 immunotherapeutic effects by lymphokine activated killer cells: Reduction of tumor and survival benefits in the murine models. Cell Immunol 29: 58–71
2. Okamoto K, Yamaguchi T, Otsuji E, Yamaoka N, Yata Y, Tsuruta H, Kitamura K (1998) Targeted chemotherapy in mice with peritoneally disseminated gastric cancer using monoclonal antibody-drug conjugate. Cancer Lett 122: 231–236
3. Yamamoto T, Arakawa F, Nakamura K, Senba T, Tomita Y, Ikeda S, Kuroki M (1999) Enhanced antitumor activity of a combination treatment with a mouse/human chimeric anti MK-1 antibody and lymphokine-activated killer cells in vitro and in a severe combined immunodeficient mouse xenograft model. Cancer Immunol Immunother 48: 165–171
4. Canevari S, Stoter G, Arietini F, Bolis G, Colnaghi MI, Warnaar SO, Bolhuis RLH (1995) Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T-lymphocytes retargeted by a bispecific monoclonal antibody. J Nat Cancer Inst 87: 1463–1469